
### **The Tropical Disease Initiative**

Comparative docking on protein structure models from ten tropical disease genomes.



Marc A. Marti-Renom

http://bioinfo.cipf.es/squ/


Structural Genomics Unit Bioinformatics Department

Prince Felipe Resarch Center (CIPF), Valencia, Spain



# Need is High in the Tail

- DALY Burden Per Disease in Developed Countries
- DALY Burden Per Disease in Developing Countries




Disease data taken from WHO, <u>World Health Report 2004</u>
DALY - Disability adjusted life years

DALY is not a perfect measure of market size, but is certainly a good measure for importance.

DALYs for a disease are the sum of the years of life lost due to premature mortality (YLL) in the population and the years lost due to disability (YLD) for incident cases of the health condition. The DALY is a health gap measure that extends the concept of potential years of life lost due to premature death (PYLL) to include equivalent years of 'healthy' life lost in states of less than full health, broadly termed disability. One DALY represents the loss of one year of equivalent full health.

# Need is High in the Tail

- DALY Burden Per Disease in Developed Countries
- DALY Burden Per Disease in Developing Countries



Disease data taken from WHO, World Health Report 2004

DALY - Disability adjusted life years

DALY is not a perfect measure of market size, but is certainly a good measure for importance.

DALYs for a disease are the sum of the years of life lost due to premature mortality (YLL) in the population and the years lost due to disability (YLD) for incident cases of the health condition. The DALY is a health gap measure that extends the concept of potential years of life lost due to premature death (PYLL) to include equivalent years of 'healthy' life lost in states of less than full health, broadly termed disability. One DALY represents the loss of one year of equivalent full health.

# "Unprofitable" Diseases and Global DALY (in 1000's)

Malaria*	46,486
Tetanus	7,074
Lymphatic filariasis*	5,777
Syphilis	4,200
Trachoma	2,329
Leishmaniasis*	2,090
Ascariasis	1,817
Schistosomiasis*	1,702
Trypanosomiasis*	1,525


Trichuriasis	1,006
Japanese encephalitis	709
Chagas Disease*	667
Dengue*	616
Onchocerciasis*	484
Leprosy*	199
Diphtheria	185
Poliomyelitise	151
Hookworm disease	59

Disease data taken from WHO, World Health Report 2004
DALY - Disability adjusted life year in 1000's.

<sup>\*</sup> Officially listed in the WHO Tropical Disease Research disease portfolio.


# Modeling Genomes

data from models generated by ModPipe (Eswar, Pieper & Sali)



### **AnnoLyze**

Predicting binding sites in protein structure models.




http://bioinfo.cipf.es/sgu/services/DBAli/
http://bioinfo.cipf.es/sgu/services/TDIModels/

### DBAliv2.0 database

http://bioinfo.cipf.es/squ/services/DBAli/

http://www.salilab.org/DBAli/



- √ Fully-automatic
- ✓ Data is kept up-to-date with PDB releases
- ✓ Tools for "on the fly" classification of families.
- ✓ Easy to navigate
- ✓ Provides tools for structure analysis

### Does not provide a stable classification similar to that of CATH or SCOP

Pairwise structure alignments				
Last update:	July 5th, 2007			
Number of chains:	93,307			
Number of structure-structure comparisons:*	1,617,719,157			
Multiple structure alignments				
Last update:	March 22nd, 2007			
Number of representative chains:	31,848			
Number of families:	11,900			


#### Uses MAMMOTH for similarity detection

- ✓ VERY FAST!!!
- √ Good scoring system with significance


Ortiz AR, (2002) Protein Sci. 11 pp2606 Marti-Renom et al. 2001. Bioinformatics. 17, 746

### DBAliv2.0 database


http://bioinfo.cipf.es/squ/services/DBAli/
http://www.salilab.org/DBAli/




# Method



inherited I	igands: 4		
Ligand	Av. binding site seq. id.	Av. residue conservation	Residues in predicted binding site (size proportional to the local conservation)
MO2	59.03	0.185	48 49 52 62 63 66 67 113 116
CRY	20.00	<u>0.111</u>	23 29 31 37 44 48 49 83 85 94 96 103 121
80G	20.00	<u>0.111</u>	19 20 21 48 49 51 96 98 136
<u>ACY</u>	15.87	0.163	23 29 31 37 44 45 81 83 85 94 96 98 103 121 135



<u>1.113.1.1</u>	23.68	0.948	19 20 50 51 52 53 54 55 56 57 58 77 78 79 80 81 82 83 84 85 93 95 97 99 134 135 138 142 145
Partner	Av. binding site seq. id.	Av. residue conservation	Residues in predicted binding site (size proportional to the local conservation)




# Sensitivity .vs. Precision

	Optimal cut-off	Sensitivity (%) Recall or TPR	Precision (%)
Ligands	30%	71.9	13.7

Sensitivity = 
$$\frac{TP}{TP + FN}$$
 Precision =  $\frac{TP}{TP + FP}$ 

~90-95% of residues correctly predicted

# Comparative docking



# **Summary table**

#### models with inherited ligands


from 16,284 good models, 295 inherited a ligand/substance with at least one compound already approved by FDA and ready to be used from ZINC

	Transcripts	Good	Ligands	Lipinski	Lipinski+ZINC	FDA+ZINC
C. hominis	3,886	886	183	131	28	12 (10)
C. parvum	3,806	949	219	145	30	12 (10)
L. major	8,274	1,845	488	334	84	44 (34)
М. Іергае	1,605	1,321	286	189	39	29 (25)
M. tuberculosis	3,991	2,887	404	285	71	44 (37)
P. falciparum	5,363	1,057	271	191	48	20 (16)
P. vivax	5,342	1,042	267	177	37	18 (15)
T. brucei	921	1,795	440	309	94	46 (36)
T. cruzi	19,607	3,915	730	493	127	62 (52)
T. gondii	7,793	587	174	124	28	8 (7)
TOTAL	60,588	16,284	3,462	2,378	586	295 (242)

# Example of inheritance (expansion)

LmjF21.0680 from L. major "Histone deacetylase 2" (model 1)

#### Template 1t64A a human HDAC8 protein.




	Origen	Formula	Name	Cov.	Seq, Id. (%)
ZN	X-ray	Zn <sup>2+</sup>	Zinc ion		
NA	X-ray	Na <sup>+</sup>	Sodium ion		
CA	X-ray	Ca <sup>2+</sup>	Calcium ion		
TSN	X-ray	C <sub>17</sub> H <sub>22</sub> N <sub>2</sub> O <sub>3</sub>	Trichostatin A		
ѕнн	Expanded	C <sub>14</sub> H <sub>20</sub> N <sub>2</sub> O <sub>3</sub>	Octadenioic acid hudroxyamide phenylamide	100.00	83.8

# Example of inheritance (inheritance)

LmjF21.0680 from L. major "Histone deacetylase 2" (model 1)

	Formula	Name	Cov.	Seq, Id. (%)	Residues
TSN	C <sub>17</sub> H <sub>22</sub> N <sub>2</sub> O <sub>3</sub>	Trichostatin A	100.00	90.9	90 131 132 140 141 167
sнн	C <sub>14</sub> H <sub>20</sub> N <sub>2</sub> O <sub>3</sub>	Octadenioic acid hudroxyamide phenylamide	100.00	90.9	169 256 263 293 295



#### suberoylanilide hydroxamic acid

#### **Pharmacological Action:**

Anti-Inflammatory Agents, Non-Steroidal
Antineoplastic Agents
Enzyme Inhibitors
Anticarcinogenic Agents

Inhibits histone deacetylase I and 3




#### trichostatin A

#### **Pharmacological Action:**

Antibiotics, Antifungal
Enzyme Inhibitors
Protein Synthesis Inhibitors

chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription

	LmjF21.0680.1.pdb
Template	It64A
Seq. Id (%)	38.00
MPQS	1.47



## Example of inheritance (CDD-Roos-literature)

LmjF21.0680 from L. major "Histone deacetylase 2" (model 1)

Proc. Natl. Acad. Sci. USA Vol. 93, pp. 13143–13147, November 1996 Medical Sciences

# Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase

(cyclic tetrapeptide/Apicomplexa/antiparasitic/malaria/coccidiosis)

Sandra J. Darkin-Rattray\*†, Anne M. Gurnett\*, Robert W. Myers\*, Paula M. Dulski\*, Tami M. Crumley\*, John J. Allocco\*, Christine Cannova\*, Peter T. Meinke‡, Steven L. Colletti‡, Maria A. Bednarek‡, Sheo B. Singh§, Michael A. Goetz§, Anne W. Dombrowski§, Jon D. Polishook§, and Dennis M. Schmatz\*

Departments of \*Parasite Biochemistry and Cell Biology, ‡Medicinal Chemistry, and §Natural Products Drug Discovery, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065


ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2004, p. 1435–1436 0066-4804/04/\$08.00+0 DOI: 10.1128/AAC.48.4.1435–1436.2004 Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Vol. 48, No. 4

Antimalarial and Antileishmanial Activities of Aroyl-Pyrrolyl-Hydroxyamides, a New Class of Histone Deacetylase Inhibitors

### **Models database**

http://bioinfo.cipf.es/squ/services/TDIModels/



# **Acknowledgments**







### **COMPARATIVE MODELING Andrej Sali**

M. S. Madhusudhan **Narayanan Eswar** Min-Yi Shen

Ursula Pieper

Ben Webb

Maya Topf (Birbeck College)

#### **MODEL ASSESSMENT**

David Eramian Min-Yi Shen Damien Devos

FUNCTIONAL ANNOTATION Andrea Rossi (Rinat-Pfizer) Fred Davis (Janelia Fram)

#### **FUNDING**

Prince Felipe Research Center Generalitat Valenciana STREP UE Grant Marie Curie Reintegration Grant

#### **MODEL ASSESSMENT**

Francisco Melo (CU)
Alejandro Panjkovich (CU)

#### STRUCTURAL GENOMICS

Stephen Burley (SGX) John Kuriyan (UCB) NY-SGXRC

#### MAMMOTH Angel R. Ortiz

FUNCTIONAL ANNOTATION
Fatima Al-Shahrour
Joaquin Dopazo

#### **BIOLOGY**

Jeff Friedman (RU)
James Hudsped (RU)
Partho Ghosh (UCSD)
Alvaro Monteiro (Cornell U)
Stephen Krilis (St.George H)

Tropical Disease Initiative
Stephen Maurer (UC Berkeley)
Arti Rai (Duke U)
Andrej Sali (UCSF)
Ginger Taylor (TSL)

#### **CCPR Functional Proteomics**

Patsy Babbitt (UCSF)
Fred Cohen (UCSF)
Ken Dill (UCSF)
Tom Ferrin (UCSF)
John Irwin (UCSF)
Matt Jacobson (UCSF)
Tack Kuntz (UCSF)
Andrej Sali (UCSF)
Brian Shoichet (UCSF)
Chris Voigt (UCSF)

#### FVΔ

Burkhard Rost (Columbia U) Alfonso Valencia (CNB/UAM)

#### CAMP

Xavier Aviles (UAB)
Hans-Peter Nester (SANOFI)
Ernst Meinjohanns (ARPIDA)
Boris Turk (IJS)
Markus Gruetter (UE)
Matthias Wilmanns (EMBL)
Wolfram Bode (MPG)

http://bioinfo.cipf.es/sgu/